These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
14. Design and engineering of deimmunized biotherapeutics. Griswold KE; Bailey-Kellogg C Curr Opin Struct Biol; 2016 Aug; 39():79-88. PubMed ID: 27322891 [TBL] [Abstract][Full Text] [Related]
15. A divide-and-conquer approach to determine the Pareto frontier for optimization of protein engineering experiments. He L; Friedman AM; Bailey-Kellogg C Proteins; 2012 Mar; 80(3):790-806. PubMed ID: 22180081 [TBL] [Abstract][Full Text] [Related]
16. Clinical validation of the "in silico" prediction of immunogenicity of a human recombinant therapeutic protein. Koren E; De Groot AS; Jawa V; Beck KD; Boone T; Rivera D; Li L; Mytych D; Koscec M; Weeraratne D; Swanson S; Martin W Clin Immunol; 2007 Jul; 124(1):26-32. PubMed ID: 17490912 [TBL] [Abstract][Full Text] [Related]
17. Accurate prediction for atomic-level protein design and its application in diversifying the near-optimal sequence space. Fromer M; Yanover C Proteins; 2009 May; 75(3):682-705. PubMed ID: 19003998 [TBL] [Abstract][Full Text] [Related]
18. Accurate prediction of immunogenic T-cell epitopes from epitope sequences using the genetic algorithm-based ensemble learning. Zhang W; Niu Y; Zou H; Luo L; Liu Q; Wu W PLoS One; 2015; 10(5):e0128194. PubMed ID: 26020952 [TBL] [Abstract][Full Text] [Related]
19. In silico analysis of MHC-I restricted epitopes of Chikungunya virus proteins: Implication in understanding anti-CHIKV CD8(+) T cell response and advancement of epitope based immunotherapy for CHIKV infection. Pratheek BM; Suryawanshi AR; Chattopadhyay S; Chattopadhyay S Infect Genet Evol; 2015 Apr; 31():118-26. PubMed ID: 25643869 [TBL] [Abstract][Full Text] [Related]